BeyondSpring (BYSI) Files for $100M IPO

November 15, 2016 12:35 PM EST
Get Alerts BYSI Hot Sheet
Trade BYSI Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

BeyondSpring Inc. (Nasdaq: BYSI) filed a registration with the U.S. SEC for an IPO of its ordinary shares. The proposed maximum offering price is $100 million.

Underwriters are Citigroup, Guggenheim Securities, FBR, China Renaissance, and Trout Capital.

BeyondSpring is a global clinical stage biopharmaceutical company focused on the development of innovative cancer therapies.

BeyondSpring continued, We are advancing our lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia, a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer, or NSCLC. Plinabulin has also entered the first of a number of planned Phase 1/2 clinical trials to investigate its therapeutic potential in combination with the immuno-oncology agent nivolumab.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories


Related Entities

Citi, IPO, Guggenheim

Add Your Comment